Skip to main content
SpringerLink
Log in
Book cover

Neuroleptika Rückschau 1952–1986, Künftige Entwicklungen pp 153–167Cite as

Zukunftsperspektiven der Neuroleptika

  • Conference paper

  • 19 Accesses

Part of the book series: Tropon-Symposium ((BAYERZNS,volume 2))

Zusammenfassung

Die Beurteilung der Zukunftsperspektiven der Neuroleptika (NL) muß zunächst einmal von einer Analyse der Nutzen-Nebenwirkungsbeziehung sowie des Wirkungsmechanismus auf der Basis bisher vorliegender Ergebnisse ausgehen. Die Überlegenheit von NL gegenüber Plazebo konnte in kontrollierten Studien sowohl in der Behandlung akuter psychotischer Symptome (Davis et al. 1983) als auch in der Prävention psychotischer Rezidive nachgewiesen werden (Carpenter et al. 1982; Pietzcker et al. 1986).

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Albus M (1983) Biochemical and clinical investigations with regard to plus and minus symptomatology in schizophrenia. Comm VII. World Congress of Psychiatry 1983

    Google Scholar 

  • Alfredsson G, Harnryd C, Wiesel FA (1985) Effects of sulpiride and chlorpromazine on autistic and positive psychotic symptoms in schizophrenic patients: relationship to drug concentrations. Psychopharmacology 85: 8–13

    Article  PubMed  CAS  Google Scholar 

  • Andreasen NC, Smith MR, Jacoby CG et al. (1982) Ventricular enlargement in schizophrenia: definition and prevalence. Am J Psychiatry 139: 292–296

    PubMed  CAS  Google Scholar 

  • Arnt J, Christensen AV, Hyttel J, Larsen J-J, Svendsen O (1983) Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activity. Eur J Pharmacol 86: 185–198

    Article  Google Scholar 

  • Baldessarini RJ, Davis JM (1980) What is the best maintenance dose of neuroleptics in schizophrenia? Psychiat Res 3: 115–122

    Article  CAS  Google Scholar 

  • Battegay R, Cotar B, Fleischhauer J, Rauchfleisch U (1977) Results and side effects of treatment with clozapine ( Leponex R ). Compr Psychiatry 18: 423–428

    Article  PubMed  CAS  Google Scholar 

  • Beckmann H, Haas S (1980) High dose diazepam in schizophrenia. Psychopharmacology 71: 7982

    Article  Google Scholar 

  • Benkert O, Hippius H (1986) Psychiatrische Pharmakotherapie. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Bleuler M (1972) Die schizophrenen Geistesstörungen im Lichte langjähriger Kranken- und Familiengeschichten. Thieme, Stuttgart

    Google Scholar 

  • Boyer P (1983) Evaluation of the desinhibitory effect of some neuroleptics at low doses in controlled trials. Comm. VII. World Congress of Psychiatry 1983

    Google Scholar 

  • Brown R, Colter N, Corsellis JAN et al. (1986) Postmortem evidence of structural brain changes in schizophrenia. Arch Gen Psychiatry 43: 36–42

    Article  PubMed  CAS  Google Scholar 

  • Carpenter W (1986) Early, targeted pharmacotherapeutic intervention in schizophrenia. J Clin Psychiatry 47 (5): 23–29

    PubMed  Google Scholar 

  • Carpenter WT, Stephens HJ, Rey AC, Hanlon TE, Heinrichs DW (1982) Early intervention vs. continuous pharmacotherapy of schizophrenia. Psychopharmacol Bull 18: 21–23

    Google Scholar 

  • Ciompi L, Müller C (1976) Lebensweg und Alter der Schizophrenen. Eine katamnestische Langzeitstudie bis ins Senium. Springer, Berlin Heidelberg New York

    Google Scholar 

  • Corsini GU, Piccardi MP, Bocchetta A, Bernardi F, Del Zompo M (1981) Behavioral effects of apomorphine in man: Dopamine receptor implications. In: Corsini GU, Gessa GL (eds) Apomorphine and other Dopaminomimetics, vol 2: Clinical pharmacology. Raven Press, New York, pp 13–24

    Google Scholar 

  • Crow TJ (1980) Molecular pathology of schizophrenia: More than one disease process? Br Med J 280: 66–68

    Article  PubMed  CAS  Google Scholar 

  • Csernansky JG, Holman CA, Hollister LE (1983) Variability and the dopamine hypothesis of schizophrenia. Schizophr Bull 9 (3): 325–328

    PubMed  CAS  Google Scholar 

  • Dabbagh M, Stanley S, Gershon S (1985) New antipsychotic agents: clinical studies. In: Burrows GD, Norman TR, Davis B (eds) Antipsychotics. Elsevier, Amsterdam, pp 147–161

    Google Scholar 

  • Davis JM, Janicak P, Linden R, Moloney J, Pavkovic J (1983) Neuroleptics and psychotic disorders. In: Coyle JT, Enna SJ (eds) Neuroleptics: neurochemical, behavioral and clinical perspectives. Raven Press, New York, pp 15–64

    Google Scholar 

  • Delini-Stula A (1986) Neuroanatomical, neuropharmacological and neurobiochemical target systems for antipsychotic activity of neuroleptics. Pharmacopsychiatry 19: 134–139

    Article  PubMed  CAS  Google Scholar 

  • Dieterle DM, Ackenheil M, Müller-Spahn F, Kapfhammer HP (1987) Zotepine a neuroleptic drug with a bipolar therapeutic profile. Pharmacopsychiatry [Special Issue I] 20: 52–57

    Article  CAS  Google Scholar 

  • Donaldson SR, Gelenberg AJ, Baldessarini RJ (1983) The pharmacologic treatment of schizophrenia: a progress report. Schizophr Bull 9 (4): 504–527

    PubMed  CAS  Google Scholar 

  • Edwards J, Alexander JR, Alexander MS et al. (1980) Controlled trial of sulpiride in chronic schizophrenic patients. Br J Psychiatry 137: 522–529

    Article  PubMed  CAS  Google Scholar 

  • Goldberg SC (1985) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 11: 453–456

    PubMed  CAS  Google Scholar 

  • Goldstein MJ (1970) Premorbid adjustment, paranoid status, and patterns of response to phenothiazines in acute schizophrenia. Schizophr Bull 3: 24–37

    Google Scholar 

  • Goldstein MJ, Rodnick EH, Evans JR, May PRA, Steinberg MR (1978) Drug and family therapy in the after care treatment of acute schizophrenics. Arch Gen Psychiatry 35: 1169

    Article  PubMed  CAS  Google Scholar 

  • Grabowski-Anden M, Anden NE (1983) Stimulation of postsynaptic DA2-Receptors produces jerks in reserpin-treated rats. J Pharm Pharmacol 35: 543–545

    Article  Google Scholar 

  • Gravem A, Bugge A (1981) Cis(Z)-clopenthixol and clopenthixol in the treatment of acute psychoses and exacerbations of chronic psychoses. Acta Psychiat Scand [Suppl] 294: 13

    CAS  Google Scholar 

  • Gravem A, Engstrand E, Guleng RJ (1978) Cis(Z)-clopenthixol in chronic psychiatric patients. Acta Psychiat Scand 58: 384–388

    Article  PubMed  CAS  Google Scholar 

  • Harding CM, Brooks CW, Takamara A, Strauss JS (1982) What happens to chronic psychiatric patients as they grow older? The Vermont Story. NIMH-Conference, Bethesda, 1–8 June 1982

    Google Scholar 

  • Holden JMC, Hsu W, Itil TM et al. (1971) Predictor patterns in the management of therapy-resistant schizophrenia. Dis Nerv Syst 32: 260–268

    PubMed  CAS  Google Scholar 

  • Hollister LE, Overall JE, Kimbell I et al. (1974) Specific indications for different classes of phenothiazines Arch Gen Psychiatry 30: 94–99

    CAS  Google Scholar 

  • Huber G, Gross G, Schüttler R (1979) Schizophrenie. Eine Verlaufs- und sozialpsychiatrische Langzeitstudie. Springer, Berlin Heidelberg New York

    Google Scholar 

  • Jackson JH (1959) The factors of insanities (1894). In: Selected Writings, vol 2. Staples, London, p 411

    Google Scholar 

  • Janke W (1965) Untersuchungen zur Frage von Wirkungsunterschieden von Fluphenazin nach erst- und mehrmaliger Applikation. Psychopharmacology 7 (5): 349–365

    Article  CAS  Google Scholar 

  • Jimerson DC, Kaminen DPM van, Post RM, Docherty JP, Bunney WE Jr (1982) Diazepam in schizophrenia: a preliminary doubleblind trial. Am J Psychiatry 139: 489–491

    PubMed  CAS  Google Scholar 

  • Kane JM (1984) The use of depot neuroleptics: clinical experience in the United States. J Clin Psychiatry 45 (5): 5–12

    PubMed  CAS  Google Scholar 

  • Kane JM, Rifkin A, Woerner M et al. (1983) Low dose neuroleptics in the treatment of outpatient schizophrenics: I. relapse rates preliminary results. Arch Gen Psychiatry 40: 893

    Article  PubMed  CAS  Google Scholar 

  • Kapfhammer HP, Rüther E (1987) Depot-Neuroleptika. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Kebabian JW, Caine DB (1979) Multiple receptors for dopamine. Nature 277: 93–96

    Article  PubMed  CAS  Google Scholar 

  • Klein DF, Rosen B (1973) Premorbid asocial adjustment and response to phenothiazine treatment among schizophrenic inpatients. Arch Gen Psychiatry 29: 480–485

    Article  PubMed  CAS  Google Scholar 

  • Kolakowska T, Williams AO, Ardern M, Reveley MA, Jambor K, Gelder MG, Mandelbrote BM (1985) Schizophrenia with good and poor outcome; I: early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 146: 229–246

    Article  PubMed  CAS  Google Scholar 

  • Leff J, Kuipers L, Berkowitz R, Eberlein-Fries R, Sturgeon D (1984) Psychosocial relevance and benefit of neuroleptic maintenance: experience in the United Kingdom. J Clin Psychiatry 45 (5): 43–49

    PubMed  CAS  Google Scholar 

  • Linden R, Davis JM, Rubinstein R (1984) Antipsychotics in the maintenance treatment of schizophrenia. In: Stancer HC, Garfinkel PE, Rakoff VM (eds) Guidelines for the use of psychotropic drugs. MTP Press, Lancaster

    Google Scholar 

  • Mackay AVP (1980) Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 137: 379–386

    Article  PubMed  CAS  Google Scholar 

  • Marder SR, Putten T van, Mintz J, Lebell M, McKenzie J, Faltico G (1984) Maintenance therapy: new findings. In: Kane JM (ed) Drug maintenance strategies in schizophrenia. APA, Washington

    Google Scholar 

  • Matz R, Rick W, Oh D, Thompson H, Gershon S (1974) Clozapine — a potential antipsychotic agent without extrapyramidal manifestations. Curr Ther Res 16: 687–695

    PubMed  CAS  Google Scholar 

  • Mielke DH, Gallant DM, Kessler C (1977) An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels. Am J Psychiatry 134: 1371–1375

    PubMed  CAS  Google Scholar 

  • Naber D, Wirz-Justice A, Kafka MS et al. (1981) Seasonal variations in the endogenous rhythm of dopamine receptor binding in rat striatum. Biol Psychiatry 16: 831–839

    PubMed  CAS  Google Scholar 

  • Ortiz A, Gershon S (1986) The future of neuroleptic psychopharmacology. J Clin Psychiatry 47 (5): 3–11

    PubMed  Google Scholar 

  • Pietzcker A (1978) Langzeitmedikation bei schizophrenen Kranken. Nervenarzt 49: 518–533

    PubMed  CAS  Google Scholar 

  • Pietzcker A, Gaebel W, Köpcke W et al. (1986) A german multicenter study on the neuroleptic long-term therapie of schizophrenic patients. Peliminary Report. Pharmacopsychiatry 4 (19): 161–166

    Article  Google Scholar 

  • Quadbeck H (1985) In: Interdisziplinärer Workshop. Deidesheim 1985

    Google Scholar 

  • Robertson MM, Trimble MR (1982) Major tranquillizers used as antidepressants. J Affect Dis 4: 173–193

    Article  PubMed  CAS  Google Scholar 

  • Rüther E (1978) Interaction of neuroleptics clozapine and haloperidol. In: Deniker P et al. (eds) Neuro-Psychopharmacology. Pergamon Press, Oxford

    Google Scholar 

  • Sedvall G, Alfredsson G, Bjerkenstadt L, Härnryd C, Wiesel FA (1983) Possible differential effects of sulpiride and chlorpromazine on plus and minus symptomatology in schizophrenia. Relationship to drug concentrations. Comm. VII. World Congress of Psychiatry 1983

    Google Scholar 

  • Severson J, Marcusson J, Winblad B et al. (1982) Age-correlated loss of dopaminergic binding sites in human basal ganglia. J Neurochem 39: 1623–1631

    Article  PubMed  CAS  Google Scholar 

  • Sieberns S, Spechtmeyer H (1982) Cis(Z)-Clopenthixoldecanoat, ein nues Depotneuroleptikum. Int Pharmacopsychiat 17: 170–184

    CAS  Google Scholar 

  • Simpson GM, Lee JH, Shrivastava RK (1978) Clozapine in tardive dyskinesia. Psychopharmacology 56: 75–80

    Article  PubMed  CAS  Google Scholar 

  • Shimomura K, Satoh H, Hirai O et al. (1982) The central anti-serotonin activity of zotepine, a new neuroleptic, in rats. Jpn J Pharmacol 32: 405–412

    Article  PubMed  CAS  Google Scholar 

  • Sternberg E (1981) Verlaufsgesetzlichkeiten der Schizophrenie im Lichte von Langzeituntersuchungen bis zum Senium. In: Huber G (Hrsg) Schizophrenie. Stand and Entwicklungstendenzen der Forschung. Schattauer, Stuttgart New York

    Google Scholar 

  • Sulpizio A, Fowler PJ, Macko E (1978) Antagonism of fenfluramine-induced hyperthermia: a measure of central serotonin inhibition. Life Sci 22: 1439–1446

    Article  PubMed  CAS  Google Scholar 

  • Sulser F (1984) Regulation and function of noradrenaline receptor systems in brain. Neuropharmacol 23: 255–261

    Article  CAS  Google Scholar 

  • Tamminga CA, Schaffer MH (1979) Treatment of schizophrenia with ergot derivatives. Psycho-pharmacology 66: 239–242

    CAS  Google Scholar 

  • Tamminga CA, Schaffer MH, Smith RC, Davis JM (1978) Apomorphine improves schizophrenic symptoms. Science 200: 567–568

    Article  PubMed  CAS  Google Scholar 

  • Thai LJ, Horowitz SG, Duorkin B et al. (1980) Evidence for loss of brain (3H)-spiroperidol and (3H)-ADTN binding sites in rabbit brain with aging. Brain Res 192: 185–194

    Article  Google Scholar 

  • Uchida S, Honda F, Otsuka M, Satoh Y, Mori J, Ono T, Hitomi M (1979) Pharmacological study of 2-chloro-11-(2-dimethylaminoethoxy) dibenzo (b,t) thiepin (zotepine). A new neuroleptic drug. Arzneimittelforsch 29: 1588–1594

    PubMed  CAS  Google Scholar 

  • Van der Velde CD (1976) Variability of schizophrenia. Reflection of a regulatory disease. Arch Gen Psychiatry 33: 489–496

    Article  PubMed  Google Scholar 

  • Vaughn CE, Leff JP (1976) The influence of family and social factors on the course of psychiatric illness. Br J Psychiatry 129: 125

    Article  PubMed  CAS  Google Scholar 

  • Williams AO, Reveley MA, Kolakowska T et al. (1985) Schizophrenia with good and poor outcome. II: Cerebral ventricular size and its clinical significance. Br J Psychiatry 146: 239–246

    Article  PubMed  CAS  Google Scholar 

  • Wöller W, Tegeler J (1983) Späte extrapyramidale Hyperkinesen, Klinik — Prävalenz — Pathophysiologie. FortschrNeurol Psychiatr 51: 131–157

    Article  PubMed  Google Scholar 

  • Woggon B (in Discussion group) (1986) Biochemical and molecular mechanisms of action of neuroleptics, alternatives to the classical dopamine hypothesis. Pharmacopsychiatry 19: 140–144

    Article  Google Scholar 

  • Woggon B, Kuny S (1983) Cis(Z)-Clopenthixol in der Behandlung der akuten Schizophrenien. Sonderdruck aus: Clopixol Symposium, Kopenhagen, 8.-9. September 1983

    Google Scholar 

Download references

Authors
  1. F. Müller-Spahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Hippns
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. 24, rue des Fossés Saint Jacques, F-75005, Paris, France

    Pierre Pichot

  2. Psychiatrische Klinik der Technischen Universität, Ismaninger Str. 22, D-8000, München 80, Deutschland

    Hans-Jürgen Möller

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Müller-Spahn, F., Hippns, H. (1987). Zukunftsperspektiven der Neuroleptika. In: Pichot, P., Möller, HJ. (eds) Neuroleptika Rückschau 1952–1986, Künftige Entwicklungen. Tropon-Symposium, vol 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83188-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-83188-1_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-18197-2

  • Online ISBN: 978-3-642-83188-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation